Interestingly, in a recently published phase 2 trial, an IL-6 inhibitor tocilizumab was safe and well-tolerated but did not meet the primary or secondary efficacy outcomes in refractory DM and PM patients; however, only eight DM patients received tocilizumab, and the effect of the drug on pruritus was not presented (30). Here, IL6 is linked to dermatomyositis.